2024-09-02 - Analysis Report
## ABT Stock Analysis Report

**Company Overview:** Abbott Laboratories (ABT) is a global healthcare company that develops, manufactures, and markets a wide range of medical devices, pharmaceuticals, and nutritional products.

**Performance Analysis:**

**1. Relative Performance:**

* ABT's cumulative return is 41.96%, while the S&P 500 (VOO) has a cumulative return of 89.66%. This represents a significant underperformance of ABT compared to the broader market.
* The current relative underperformance of ABT against the S&P 500 is -47.7%, which places it in the lower 14.85% percentile of its historical performance range.

**2. Recent Price Action:**

* ABT's closing price is $113.27.
* The 5-day moving average is $112.95, indicating a short-term upward trend.
* The 20-day moving average is $110.9, also suggesting a positive momentum.
* The 60-day moving average is $106.71, showcasing a longer-term upward trend.

**3. Technical Indicators:**

* RSI (Relative Strength Index) is 82.52, indicating overbought territory, suggesting potential for a short-term correction.
* PPO (Percentage Price Oscillator) is 0.03, indicating a positive but weak momentum.
* The recent (20-day) relative divergence change is -8.38, signifying a potential short-term downtrend.
* The expected return is 27.09%, indicating a potential 5-year return for a current investment.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-31 | 0.74 | 10.38 B$ |
| 2024-05-02 | 0.7 | 9.96 B$ |
| 2023-11-01 | 0.82 | 10.14 B$ |
| 2023-08-03 | 0.79 | 9.98 B$ |
| 2024-07-31 | 0.79 | 9.98 B$ |

The most recent earnings report for the quarter ended July 31, 2024, shows an EPS of $0.74, exceeding analyst estimates of $0.71. Revenue for the quarter was $10.38 billion, also exceeding expectations. 

Overall, ABT has been consistently meeting or exceeding analysts' estimates, showcasing a strong financial performance.

**5. Comprehensive Analysis:**

ABT's recent price action indicates a positive momentum, with the stock trading above its short and long-term moving averages. However, its high RSI suggests potential overbought conditions, which could lead to a short-term correction. ABT has been significantly underperforming the S&P 500, highlighting its weakness compared to the broader market. Despite this, the company continues to report strong financial results, exceeding analysts' expectations.

**6. Recommendation:**

While ABT's recent performance and earnings have been positive, its high RSI and relative underperformance compared to the market suggest cautious optimism. Investors should monitor its future performance and watch for potential short-term corrections. While the company's long-term prospects are promising, it is essential to evaluate individual investment goals and risk tolerance before considering investing in ABT. 
